Charles M. Perou, PhD, a UNC Lineberger member and a professor of genetics, pathology and laboratory medicine at the UNC School of Medicine, was a co-corresponding author of a study recognized by the Clinical Research Forum.
Charles M. Perou, PhD, a UNC Lineberger member and a professor of genetics, pathology and laboratory medicine at the UNC School of Medicine, was a co-corresponding author of a study recognized by the Clinical Research Forum.

OncLive has named UNC Lineberger Comprehensive Cancer Center’s Charles M. Perou, PhD, as a 2019 Giant of Cancer Care. Perou is being honored for his scientific achievements that have advanced the field of cancer diagnostics and is one of 15 cancer clinicians and scientists who will be recognized at the Giants of Cancer Care Winners’ Reception on May 30 in Chicago.

Perou is internationally renowned for his research that demonstrated how breast cancer can be classified into different subtypes based on biological differences, a finding that continues to improve clinical treatments and inform research. These insights into genetic and genomic characteristics have contributed to the development of precision medicine in cancer.

OncLive is a print and digital publication that provides oncology professionals with resources and information on the provision of cancer care, from new technology to treatment advances to important regulatory decisions.

Perou, who is the May Goldman Shaw Distinguished Professor of Molecular Oncology in the Department of Genetics and the Department of Pathology & Laboratory Medicine at the UNC School of Medicine, has won many notable honors for his research accomplishments, including the Susan G. Komen’s Brinker Award for Scientific Distinction. In addition, his published scientific findings have consistently earned the designation as one of the most highly cited researchers in clinical medicine.

Perou and his fellow Giants of Cancer Care were nominated by the oncology community and then vetted by a seven-member advisory board of world-renowned oncologists. The finalists in were then voted on by a 115-plus member selection committee comprising world leading cancer specialists.

“We are looking forward to honoring each of these outstanding individuals at this year’s Giants of Cancer Care celebration,” said Michael J. Hennessy Jr., president of MJH Associates, parent company of OncLive. “Each inductee has worked hard to propel the field of oncology forward through groundbreaking and innovative contributions in cancer treatment, diagnosis, and research.”